ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Antitrypanosomal secondary metabolites from medicinal plants: a review.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antiparasitic Activity of Sesquiterpene γ-Lactones and the Search for New Pharmaceutical Agents.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human African trypanosomiasis (HAT) or sleeping sickness is caused by two subspecies of extracellular protozoan parasites, namely, Trypanosoma brucei gambiense and T. brucei rhodesiense. On the other hand, Chagas disease is caused by Trypanosoma cruzi. There are currently six drugs available for the treatment of African sleeping sickness, namely, pentamidine, suramin, melarsoprol, nifurtimox, eflornithine, and fexinidazole. Besides, benznidazole and nifurtimox are drugs that are currently used for the treatment of Chagas disease. Most of the current chemotherapies for the treatment of HAT and Chagas disease are unsuitable for prescription for various reasons including high toxicity, poor efficacy, undesirable route of administration, and drug resistance. Medicinal plants are potential sources of therapeutics for many diseases. Thus, a search for compounds from plants that are active against trypanosomes could pave the way to the discovery of antitrypanosomal drugs. Therefore, the current review evaluates the potential of the secondary metabolites from medicinal plants for antitrypanosomal drug development. The literature review in the field of antitrypanosomal secondary metabolites from medicinal plants has been documented. Hence, the present study involves the discussion of antitrypanosomal natural products from medicinal plants that were not reported in these review articles present in literature. The literature search was carried out in various databases including ScienceDirect, Google Scholar, tandfonline.com, Journal of Natural Products, MDPI, WILEY Online Library, tandfonline.com, and The Lancet. In this article, the secondary metabolites organized in different classes including alkaloids, terpenoids, and flavonoids that have potency against trypanosomes are discussed.
Indexed as
Identifiers
40410549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.